firstinclass

Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously…

MILAN -- An investigational protein drug called dazodalibep with broad-spectrum activity against autoimmune…

<!-- Name:DistributionId Value:8798603 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

The FDA granted accelerated approval to the bispecific monoclonal antibody mosunetuzumab…

PARIS and CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering…

PARIS et CAMBRIDGE, Mass., 02 nov. 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société de biotechnologie en phase de développement clinique…

FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments…

Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high…

WATERTOWN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver…

A first-in-class investigational agent offered symptom relief to patients with active…